The biopharma sector has had quite a year. Under FDA Commissioner Scott Gottlieb, the regulator approved a record number of drugs and helped usher in innovative gene therapy treatments. Behavioral health drugs also marked a milestone with the approval of Otsuka Pharmaceutical’s Abilify MyCite, embedded with a sensor developed by Proteus Digital Health to remotely monitor medication adherence for people with schizophrenia and bipolar disorders.
{iframe}https://medcitynews.com/2017/12/biopharma-trends-tax-law-impact-in-2018/?_hsenc=p2ANqtz-9L64ZN-TGXODJOduJfGmWjaJm7hdLo33l8YxR_XicM1DKN6b-XmbKjPIaZn2-LBULaccvMLC5kKYbNxhcwekNOg9OiDg&_hsmi=59692921{/iframe}